

China Pharma Holdings, Inc. (CPHI)

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001106644

China Pharma Holdings, Inc. CPHI; healthcare	
Grade	E A B C D E weakest fifth of 371 graded peers percentile 93.2; sampling error 2.5 points; lower is stronger
Rank	346 of 371
Profitability	D percentile 73.2
Solvency	D percentile 73.2
Growth and financing	D percentile 69.0
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$31.0M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	dilution, late filer not computable: distress
Inputs computable	8 of 14
Graded from	filings received through Apr 1, 2026 191 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	\$0.97 2026-10-08; market equity \$41.7M
Price used in grade	None



E, the bear

weakest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescan


split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: D from Apr 21, 2015, E from Apr 21, 2016

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Apr 1, 2026

(the "Company", "China Pharma", "we", "us", or "our") is a Nevada holding company. China Pharma is not a Chinese operating company and all the operations are conducted by our wholly owned subsidiary, Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson") and Helpson's subsidiaries in China. We, through Helpson, are principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and

medical conditions prevalent in the People's Republic of China (the "PRC"). All of the operations are conducted in the PRC, where the manufacturing facilities are located.

The fourteen inputs


lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 73.2						
Gross profitability		(0.4%)	32.2%	97.8	372	2025-12-31
Return on invested capital		not computable	9.3%			latest aligned inputs end 2018-12-31; latest annual assets end 2025-12-31
Accruals ratio		(14.5%)	(6.6%)	30.9	811	2025-12-31
Gross margin stability, five years		16.9 pts	2.8 pts	90.9	243	2025-12-31
Solvency, sleeve percentile 73.2						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(3.85)	(0.31)	50.5	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			latest aligned inputs end 2020-12-31; latest annual assets end 2025-12-31
Interest coverage		not computable	(4.51x)			interest expense must exceed \$100,000
Current ratio		0.32x	2.96x	95.9	839	2025-12-31
Growth and financing, sleeve percentile 69.0						
Revenue growth, three-year compound		(20.0%)	10.0%	89.4	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 14
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		20.3%	2.1%	20.9	704	2025-12-31
Net share issuance, one year		1,142.3%	2.5%	96.8	634	2026-03-25

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 1142.3%
Late filer	found 1 NT 10-K/Q filings in the last eight quarters



Rank	Company	Percentile	Letter	Warnings
341	Beyond Air, Inc. (XAIR)	91.9	E	dilution, short runway, distress
342	Precision Biosciences Inc. (DTIL)	92.2	E	dilution, fortress balance sheet
343	Elutia Inc. (ELUT)	92.4	E	short runway, fortress balance sheet
344	Airsculpt Technologies, Inc. (AIRS)	92.7	E	late filer
345	Sutro Biopharma, Inc. (STRO)	93.0	E	dilution, short runway, distress, fortress balance sheet
346	China Pharma Holdings, Inc. (CPHI) <	93.2	E	dilution, late filer
347	Fortress Biotech, Inc. (FBIO)	93.6	E	fortress balance sheet
348	Fortress Biotech, Inc. (FBIOP)	93.6	E	fortress balance sheet
349	Co-Diagnostics, Inc. (CODX)	94.1	E	dilution, short runway, fortress balance sheet
350	Kyntra BIO, Inc. (KYNB)	94.3	E	
351	Celularity Inc. (CELU)	94.6	E	short runway, late filer

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(54.6%)	8.0%	11
Distance from 52-week high	(88.1%)	(31.4%)	5
EBIT to enterprise value	(7.1%)	(1.5%)	36
Free cash flow yield	0.2%	(1.0%)	56
Book value to price	0.88	0.28	83
Sales to price	0.10	0.31	25
Composite equity issuance, five years	615.7%	20.3%	98
Relative strength against the sector, log excess return	(1.00)	(0.14)	11

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$304,874
Operating cash flow, four quarters	-\$140,490
Months of runway	26.0
Days since last periodic filing	56 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	\$235,835

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	-\$131,950	2025-12-31	2026-04-01	10-K	0001213900-26-038521
2	assets	us-gaap:Assets	\$31.0M	2025-12-31	2026-04-01	10-K	0001213900-26-038521
3	operating income	us-gaap:OperatingIncomeLoss	-\$10.4M	2018-12-31	2020-03-30	10-K	0001213900-20-008020
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$10.9M	2025-12-31	2026-04-01	10-K	0001213900-20-008020
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$109,989	2018-12-31	2020-03-30	10-K	0001213900-20-008020
6	total debt	us-gaap:LongTermDebt	\$6.5M	2018-12-31	2019-03-28	10-K	0001213900-19-005094
7	book equity	us-gaap:StockholdersEquity	\$30.2M	2018-12-31	2021-03-26	10-K	0001213900-21-017981
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$1.2M	2018-12-31	2020-03-30	10-K	0001213900-20-008020
9	total debt	us-gaap:LongTermDebt	\$9.2M	2017-12-31	2018-04-02	10-K	0001213900-18-003895
10	book equity	us-gaap:StockholdersEquity	\$43.1M	2017-12-31	2020-03-30	10-K	0001213900-20-008020
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$2.0M	2017-12-31	2019-03-28	10-K	0001213900-19-005094
12	net income	us-gaap:NetIncomeLoss	-\$3.2M	2025-12-31	2026-04-01	10-K	0001213900-26-038521
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$148,261	2025-12-31	2026-04-01	10-K	0001213900-26-038521
14	assets	us-gaap:Assets	\$14.9M	2024-12-31	2026-04-01	10-K	0001213900-26-038521
15	revenue	us-gaap:Revenues	\$4.1M	2025-12-31	2026-04-01	10-K	0001213900-26-038521
16	gross profit	us-gaap:GrossProfit	-\$2.0M	2024-12-31	2026-04-01	10-K	0001213900-26-038521
17	revenue	us-gaap:Revenues	\$4.5M	2024-12-31	2026-04-01	10-K	0001213900-26-038521
18	gross profit	us-gaap:GrossProfit	-\$281,085	2023-12-31	2025-03-31	10-K	0001213900-25-026280
19	revenue	us-gaap:Revenues	\$7.0M	2023-12-31	2025-03-31	10-K	0001213900-25-026280
20	gross profit	us-gaap:GrossProfit	-\$493,916	2022-12-31	2024-04-01	10-K	0001213900-24-028731
21	revenue	us-gaap:Revenues	\$8.1M	2022-12-31	2024-04-01	10-K	0001213900-24-028731
22	gross profit	us-gaap:GrossProfit	\$349,270	2021-12-31	2023-03-30	10-K	0001213900-23-024710
23	revenue	us-gaap:Revenues	\$9.6M	2021-12-31	2023-03-30	10-K	0001213900-23-024710
24	current assets	us-gaap:AssetsCurrent	\$2.3M	2025-12-31	2026-04-01	10-K	0001213900-26-038521
25	current liabilities	us-gaap:LiabilitiesCurrent	\$7.4M	2025-12-31	2026-04-01	10-K	0001213900-26-038521
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$47.2M	2025-12-31	2026-04-01	10-K	0001213900-26-038521
27	operating income	us-gaap:OperatingIncomeLoss	-\$3.2M	2025-12-31	2026-04-01	10-K	0001213900-26-038521
28	book equity	us-gaap:StockholdersEquity	\$22.7M	2025-12-31	2026-04-01	10-K	0001213900-26-038521
29	liabilities	us-gaap:Liabilities	\$8.3M	2025-12-31	2026-04-01	10-K	0001213900-26-038521
30	total debt	us-gaap:LongTermDebt	\$5.2M	2020-12-31	2021-03-26	10-K	0001213900-21-017981
31	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$957,653	2020-12-31	2022-03-30	10-K	0001213900-22-016151
32	operating income	us-gaap:OperatingIncomeLoss	-\$2.6M	2020-12-31	2022-03-30	10-K	0001213900-22-016151
33	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$2.7M	2020-12-31	2022-03-30	10-K	0001213900-22-016151
34	interest expense	us-gaap:InterestExpense	\$27,272	2025-12-31	2026-04-01	10-K	0001213900-26-038521
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$51,145	2018-12-31	2020-03-30	10-K	0001213900-20-008020
36	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$3.3M	2018-12-31	2020-03-30	10-K	0001213900-20-008020

37	current assets	us-gaap:AssetsCurrent	\$8.7M	2018-12-31	2020-03-30	10-K	0001213900-20-008020
38	current liabilities	us-gaap:LiabilitiesCurrent	\$10.1M	2018-12-31	2020-03-30	10-K	0001213900-20-008020
39	current assets	us-gaap:AssetsCurrent	\$12.3M	2017-12-31	2019-03-28	10-K	0001213900-19-005094
40	current liabilities	us-gaap:LiabilitiesCurrent	\$9.2M	2017-12-31	2019-03-28	10-K	0001213900-19-005094
41	assets	us-gaap:Assets	\$16.5M	2023-12-31	2025-03-31	10-K	0001213900-25-026280
42	assets	us-gaap:Assets	\$17.8M	2022-12-31	2024-04-01	10-K	0001213900-24-028731
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	40,522,002	2026-03-25	2026-04-01	10-K	0001213900-26-038521
44	shares outstanding	dei:EntityCommonStockSharesOutstanding	32,619,109	2025-03-24	2025-03-31	10-K	0001213900-25-026280